Trevi Therapeutics Inc logo

Trevi Therapeutics Inc

1
NAS:TRVI (USA)  
$ 2.64 -0.105 (-3.83%) 12:35 PM EST
At Loss
P/B:
1.96
Market Cap:
$ 173.69M
Enterprise V:
$ 87.51M
Volume:
260.56K
Avg Vol (2M):
248.14K
Volume:
260.56K
At Loss
Avg Vol (2M):
248.14K

Business Description

Description
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Name Current Vs Industry Vs History
Cash-To-Debt 63.25
Equity-to-Asset 0.93
Debt-to-Equity 0.02
Debt-to-EBITDA -0.05
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 97.01
9-Day RSI 93.24
14-Day RSI 88.66
6-1 Month Momentum % -37.21
12-1 Month Momentum % -48.28

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 18.16
Quick Ratio 18.16
Cash Ratio 17.18

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -49.8
Shareholder Yield % 3.08
Name Current Vs Industry Vs History
ROE % -26.55
ROA % -23.69
ROIC % -445.75
ROC (Joel Greenblatt) % -2087.12
ROCE % -25.48

Financials (Next Earnings Date:2024-03-15 Est.)

TRVI's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:TRVI

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Trevi Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.27
Beta 1.12
Volatility % 112.23
14-Day RSI 88.66
14-Day ATR ($) 0.199854
20-Day SMA ($) 1.69625
12-1 Month Momentum % -48.28
52-Week Range ($) 0.97 - 3.5
Shares Outstanding (Mil) 63.86

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Trevi Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Trevi Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Trevi Therapeutics Inc Frequently Asked Questions

What is Trevi Therapeutics Inc(TRVI)'s stock price today?
The current price of TRVI is $2.64. The 52 week high of TRVI is $3.50 and 52 week low is $0.97.
When is next earnings date of Trevi Therapeutics Inc(TRVI)?
The next earnings date of Trevi Therapeutics Inc(TRVI) is 2024-03-15 Est..
Does Trevi Therapeutics Inc(TRVI) pay dividends? If so, how much?
Trevi Therapeutics Inc(TRVI) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1